WealthSpring Partners’s AbbVie ABBV Stock Holding History

WealthSpring Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$275K	Hold	1,093	–	–	0.24%	57
2026 Q1	$238K	Hold	1,093	–	–	0.22%	62
2025 Q4	$250K	Buy	+1,093	New	+$249K	0.26%	50
2023 Q3	$366K	Hold	2,456	–	–	0.27%	48
2023 Q2	$331K	Buy	2,456 +78	+3%	+$11.4K	0.24%	56
2023 Q1	$379K	Sell	2,378 -4,000	-63%	-$612K	0.29%	50
2022 Q4	$1.03M	Buy	6,378 +1,400	+28%	+$215K	0.81%	21
2022 Q3	$668K	Buy	+4,978	New	+$714K	0.59%	27

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

WealthSpring Partners's ABBV Position: Q2 2026 in Review

WealthSpring Partners held its AbbVie (ABBV) position steady in Q2 2026 at 1,093 shares worth $275K. The position accounts for 0.24% of the portfolio, ranked #57.

WealthSpring Partners first reported a position in ABBV in Q3 2022 and has held it in 8 quarters since. The position peaked at $1.03M in Q4 2022. 4,189 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

WealthSpring Partners held 1,093 shares of AbbVie worth $275K as of Q2 2026.
WealthSpring Partners left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.24% of WealthSpring Partners's portfolio in Q2 2026, its #57 holding.
WealthSpring Partners first reported a position in AbbVie in Q3 2022 and has held it in 8 quarters since.
WealthSpring Partners's AbbVie position peaked at $1.03M in Q4 2022.
4,189 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on WealthSpring Partners's 13F filing for Q2 2026, filed 5 Aug 2026.